Health
Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates
Tivoxavir marboxil (TXM), administered as a single dose in non-human primates, significantly reduced lung viremia and prevented weight loss, two key measures of antiviral activity in preclinical bird flu modelsResults build on earlier positive findings of mortality benefit for TXM in ferrets and miceFDA briefing documents in preparation for discussion of potential accelerated path to approvalData presentation to be provided at Investor Event on March 31, 2025 at 10:00 AM ET NEWTOWN, Pa., March 2
About this update from Traws Pharma, Inc.
[{"type":"image","alt":"Traws Pharma, Inc.","displaySize":"","headline":null,"caption":"Traws Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/b7f59076ee694ac5fc5d681bbcfa7af2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/O38eCot9fjUiIRrtl6lHyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b7f59076ee694ac5fc5d681bbcfa7af2","width":300,"height":300}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Tivoxavir marboxil (TXM), administered as a single dose in non-human primates, significantly reduced lung viremia and prevented weight loss, two key measures of antiviral activity in preclinical bird flu models","length":210,"tagName":"p"}]},{"val":[{"type":"text","content":"Results build on earlier positive findings of mortality benefit for TXM in ferrets and mice","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA briefing documents in preparation for discussion of potential accelerated path to approval","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"Data presentation to be provided at Investor Event on March 31, 2025 at 10:00 AM ET","length":83,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":478,"olType":false},{"type":"text","content":"NEWTOWN, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced positive topline results from a study evaluating the use of tivoxavir marboxil (TXM) as a treatment for non-human primates challenged with a non-lethal dose of H5N1 bird flu. TXM is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dose for the treatment of bird flu and seasonal influenza.","length":646,"tagName":"p"},{"type":"text","content":"In the study, ten non-human primates (NHP, five treated, five control) received a non-lethal challenge dose of H5N1 bird flu at time zero and 12 hours later received a one-time treatment of TXM, dosed at the equivalent of a human dose of 480 mg. Key assessments included body weight and lung viremia. Since flu c...